Diarrhea – Pipeline Review, 2019

Table of Content:

1. Introduction

1.1. Report Overview

2. Diarrhea - Overview

3. Executive Summary

4. Diarrhea: Pipeline Assessment

4.1. By Stage of Development

4.2. By Route of Administration

4.3.通过药物类

4.4. By Molecule Type

4.5. By Therapy Area / Indication

4.6. By Drug Target

4.7. By Sponsor

5. Diarrhea: Company & Drug Profiles

5.1. Clinical Stage

5.1.1. PBCLN-003 – Prolacta Bioscience

5.1.1.1. Company Overview

5.1.1.2. Product Description

5.1.1.3. R&D Status & Development Activities

5.1.1.4. Mechanism of Action

5.1.1.5. Molecule Type

5.1.1.6. Stage of Development

5.1.1.7. Indications

5.1.1.8. Route of Administration

5.1.1.9. Funding

5.1.2. BOS-589 – Boston Pharmaceuticals

5.1.2.1.公司概述

5.1.2.2. Product Description

5.1.2.3. R&D Status & Development Activities

5.1.2.4. Mechanism of Action

5.1.2.5. Molecule Type

5.1.2.6. Stage of Development

5.1.2.7. Indications

5.1.2.8. Route of Administration

5.1.2.9. Funding

5.1.3. RBX2660 – Rebiotix Inc.

5.1.3.1. Company Overview

5.1.3.2. Product Description

5.1.3.3. R&D Status & Development Activities

5.1.3.4. Mechanism of Action

5.1.3.5. Molecule Type

5.1.3.6. Stage of Development

5.1.3.7. Indications

5.1.3.8. Route of Administration

5.1.3.9. Funding

5.1.4. Others

5.2. Preclinical

5.2.1. Company Overview

5.2.2. Product Description

5.2.3. R&D Status & Development Activities

5.2.4. Mechanism of Action

5.2.5. Molecule Type

5.2.6. Indications

5.2.7. Route of Administration

5.2.8. Funding

6. Diarrhea: An Overview on Dormant & Discontinued Pipeline Candidates

6.1. Overview

6.2. Product Description

6.3. Reason for Discontinuation

7. Diarrhea: Additional Key Insights

7.1. Epidemiology Overview: Diarrhea

7.2. Current Market Scenario: Diarrhea Therapeutics

8. Diarrhea: News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.